CNS demyelination associated with nilotinib

Creative Commons License

Erturul Tokgöz E., Kocer B., Gokce S., Uçar M.

NEUROLOGICAL SCIENCES, vol.44, no.9, pp.3335-3339, 2023 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Letter
  • Volume: 44 Issue: 9
  • Publication Date: 2023
  • Doi Number: 10.1007/s10072-023-06827-4
  • Journal Name: NEUROLOGICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, Index Islamicus, MEDLINE, Psycinfo
  • Page Numbers: pp.3335-3339
  • Gazi University Affiliated: Yes

Abstract

As treatment options for cancer and autoimmune diseases are developing each day, iatrogenic central demyelination case reports are increasing in number. Tumor necrosis factoralpha inhibitors and immune-checkpoint inhibitors are the most frequently reported agents in iatrogenic central nervous system demyelination cases [1]. Recently, there have been reports on iatrogenic peripheral and central demyelination associated with tyrosine kinase inhibitors. Nilotinib is a second generation tyrosine kinase inhibitor targeting the Bcr-abl translocation, and used in chronic myeloid leukemia (CML) [2]. A possible central demyelination associated with the use of nilotinib will be presented in this case report.